期刊文献+

左旋泮托拉唑钠肠溶片的制备及其稳定性考察 被引量:8

Preparation and stability study of (l) -pantoprazole sodium enteric tablets
下载PDF
导出
摘要 目的:制备左旋泮托拉唑钠肠溶片并考察其稳定性。方法:以3因素3水平(碳酸钠的含量0,5%, 10%;黏合剂的种类MC,HPMC和PVP;浓度2%,5%,8%)的正交试验设计进行片芯处方筛选,并参考中国药典2000年版附录考察了制剂的稳定性。结果:确定了以聚乙烯吡咯烷酮(PVP)为黏合剂、10%碳酸钠为稳定剂的处方,恒温加速试验及长期留样试验6个月,含量及有关物质未见明显改变。结论:本法制备肠溶片的处方工艺简便,易于控制和操作。 Objective:To investigate the preparation and stability of (l)-pantoprazole sodium enteric tablets. Methods: The formulation of (l)-pantoprazole sodium enteric tablets was optimized by an orthogonal design involved in 3 factors and 3 levels [quantity of sodium carbonate (0,5%,10% ) , types of binders (MC,HPMC,PVP) and concentration of binders (2%,5%,8%)]. The stability of (l) -pantoprazole sodium enteric tablets was studied as defined in China Pharmacopoeia 2000. Results: The PVP and sodium carbonate were considered the optimal binder and stabilizer, respectively. No changes in the content and the related substances of the tablets were observed after the tablets were placed under an accelerated storage conditions for 6 months. Conclusion: The easily manipulated and stable formulation process of (l)-pantoprazole sodium enteric tablets was achieved.
出处 《中国新药杂志》 CAS CSCD 北大核心 2006年第1期41-43,共3页 Chinese Journal of New Drugs
关键词 左旋泮托拉唑钠 肠溶片 正交设计 稳定性 (l)-pantoprazole sodium enteric tablets orthogonal design stability
  • 相关文献

参考文献5

二级参考文献26

  • 1[1]Kromer W, Kohl B. Pantoprazole sodium [J]. Drugs of the Future, 1990,15(8):801-804.
  • 2[2]Kromer W, Postius S, Riedel R, et al. Pantoprazole, a novel gastric proton pump inhibitor, potently inhibits acid secretion but lacks relevant cytochrome P450 interactions [J]. J Pharmacol Exp Therap, 1990, 254:129.
  • 3[3]Doyle E, Mcdowall RD, Murkitt GS, et al. Two systems for the automated analysis of drugs in biological fluids using high-performance liquid chromatography [J]. J Chromatogr, 1990, 527:67-77.
  • 4[1]Anonymous. Pantoprazole--a third pump inhibitor[J]. Drug Ther Bull, 1997,35(2):93-94.
  • 5[2]Sachs C. Proton pump inhibitors and acid-related disease[J]. Pharmaco Therapy, 1997,17(1):22-37.
  • 6[3]Bliesath H, Huber R, Hartmaun H, et al. Dose linearity of the phar-macokinetics of the new H+/K+-ATPase inhibitor pantoprazole after single intravenous administration [J]. J Clin Pharmacol Ther, 1996,34(Suppl 1):18-24.
  • 7[4]Huber R, Hartmaun M, Bliesath H, et al. Pharmacokinetics of panto-prazole in man[J]. J Clin Pharmacol Ther, 1996,34((Suppl 1): 7-16.
  • 8[5]Wurzer H, Sohutze K, Bethke T, et al . Efficacy and safety of panto-prazole in patients with gastroesophageal reflux disease using in intravenous-oral regim[J]. Hepatogastroent, 1999,46:1809-1815.
  • 9[6]Paul J, Metz D, Marton P, et al. Pharmacodynamic equivalence of oral and iv pantoprazole in GERD patients[J]. Am J Gastroenterol, 1998,93:1622, Abstract.
  • 10[7]Metz D C, Forsmark C E, Soffer E, et al. Zollinger-Ellison syndrome patients can replace oral proton pump inhibitors with intravenous pantoprazole without losing control of acid output[N]. Paper Presented at Digestive Disease Week. 1999-05-16(19).

共引文献35

同被引文献35

引证文献8

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部